Revenue and Financial Performance - For the year ended 31 March 2023, the Group recorded a revenue of approximately HK$223.85 million, representing an increase of approximately 141.03% compared to HK$92.87 million for the year ended 31 March 2022[26]. - The Group's gross profit for the year ended 31 March 2023 was approximately HK$12.05 million, with a gross profit margin of 5.38%, down from 14.81% in the previous year[27]. - The healthcare products and services segment recorded a turnover of HK$223.66 million, with a segment loss of HK$16.12 million, an increase of approximately HK$13.77 million compared to the previous year[41]. - The loss for the year ended 31 March 2023 was approximately HK$31.75 million, a decrease of approximately HK$5.57 million compared to the loss of HK$37.32 million in the previous year[31]. - Basic and diluted loss per share for the year ended 31 March 2023 was approximately HK1.71 cents, down from HK2.68 cents in the previous year, representing a decrease in loss of approximately HK0.97 cents[32]. Business Operations and Expansion - The Group continues to deepen its medical testing business while expanding sales of medical supplies and internet medical data services to create more value for shareholders[10]. - The Group's genetic testing service is expanding both in Hong Kong and overseas, driven by increased demand for hygiene and health products due to COVID-19[20]. - The Group plans to continue expanding its genetic testing services in Hong Kong and overseas, driven by increased demand for hygiene and health products due to COVID-19[40]. - The Group is actively developing domestic healthcare equipment service business and integrating health data analysis software with healthcare equipment to provide new services[39]. - The Group's health business, including genetic testing and urine testing, creates synergies and expands the sales network through cross-selling products to various clients such as local governments and hospitals[158]. Money Lending Business - The Group is also engaged in a money lending business, diversifying its operations[21]. - Interest income from the money lending business decreased by approximately 75% to HK$0.19 million for the year ended 31 March 2023, due to the downsizing of the loan portfolio to zero balance[48]. - The Group's lending business reported interest income of HK$190,000 for the year ended March 31, 2023, a decrease of approximately 75% compared to HK$760,000 for the previous year due to a reduction in the total amount of loans issued[51]. - The Group focuses on short-term loans, with a maximum loan period of 12 months, primarily targeting corporate customers[51]. - The Group has a credit assessment process in place to evaluate potential borrowers' credit quality and define credit limits, which includes assessing financial backgrounds and collateral values[54]. Investments and Impairments - The Group acquired a 30% equity interest in Guangzhou Manrui Biotech Company Limited for approximately HK$65,129,000, which specializes in genetic testing technologies[63]. - Manrui Biotech's genetic testing technologies have not generated any income since the Group's acquisition, leading to a full impairment of the investment during the year ended March 31, 2022[63][64]. - Full impairment was made on the investment in Manrui Biotech, with no income generated since acquisition, affecting comparative profit and loss figures[105][107]. - The Group received full refunds of RMB30,000,000 (approximately HK$34,270,000) and RMB25,000,000 (approximately HK$28,558,000) from two associates that were de-registered due to COVID-19 related business plan failures[111]. Prepayments and Refunds - The Group recorded prepayments for healthcare supplies of approximately HK$89,620,000 as of 31 March 2022, including RMB22,685,000 (approximately HK$27,971,000) and RMB50,000,000 (approximately HK$61,649,000)[82]. - The Group has not received disinfectant materials from suppliers A and B, and a cancellation agreement was signed with supplier A in April 2023, resulting in a request for a full refund of approximately HK$28,889,000[91][95]. - The Group received a refund of approximately HK$23,333,000 from supplier A, with an outstanding balance of approximately HK$5,556,000 impaired[91][95]. - The total prepayments of approximately HK$106,535,000 and their recoverability of approximately HK$77,646,000 as of 31 March 2023 could not be verified due to insufficient audit evidence[94][96]. Audit and Financial Reporting - The Group's financial statements for the year ended March 31, 2023, were audited and found to give a true and fair view of its financial position, despite a qualified opinion regarding the valuation of its investment in Manrui Biotech[58][59]. - The qualification related to the opening balance of the Group's financial position as of March 31, 2023, was resolved with no qualifications for the two associates in the consolidated statement[113]. - The Audit Committee has concurred with the treatment of the investments in the two de-registered associates and the prepayment for consultant services[114]. - The Group's consolidated statement of profit or loss for the year ended March 31, 2023, shows no qualifications regarding prepayments for consultant services[116]. Future Outlook and Strategy - The Company expects to complete the disposal of Manrui Biotech on or before September 30, 2023, which would resolve audit issues for the year ending March 31, 2024[110]. - The Company plans to expand its sales market to Hong Kong and Southeast Asia, in addition to existing PRC distribution channels[135]. - The management believes that the health products and services business has a broad outlook due to increased health awareness post-COVID-19, which could provide overall returns to the company and its shareholders[158]. - The Group's management emphasizes prudent financial management to minimize risks[186][191]. Employee and Financial Management - The number of full-time employees decreased to 13 as of March 31, 2023, from 15 in 2022, due to a shift in marketing strategy[189][193]. - Employee remuneration is based on performance, experience, and market standards, with benefits including medical insurance and retirement schemes[189][193]. - The Group relies on internally generated funds and proceeds from fundraising activities for financing operations and expansion[186][191].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公佈全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 截至二零二三年三月三十一日止年度 全年業績公佈 蓮和醫療健康集團有限公司（「本公司」）董事（「董事」）會（「董事會」）僅此公佈本 公司及其附屬公司（統稱「本集團」）截至二零二三年三月三十一日止年度之經審 核綜合財務報表，連同截至二零二二年三月三十一日止年度之比較數字如下： ...

Financial Performance - Revenue for the six months ended September 30, 2022, was HK$56,407,000, a decrease of 35.6% compared to HK$87,492,000 in the same period of 2021[10]. - Gross profit for the period was HK$5,055,000, down from HK$8,813,000, reflecting a gross margin decline[10]. - The operating loss for the period was HK$1,341,000, an improvement from the operating loss of HK$3,732,000 in the previous year[10]. - The loss for the period attributable to owners of the company was HK$1,262,000, compared to HK$4,585,000 in the same period of 2021[10]. - Total comprehensive expense for the period was HK$27,732,000, significantly higher than HK$1,147,000 in the previous year[13]. - Basic and diluted loss per share was HK$0.09, an improvement from HK$0.36 in the same period of 2021[13]. - The company reported other income and gains of HK$1,131,000, compared to HK$16,000 in the previous year[10]. - Selling and distribution costs were HK$974,000, a decrease from HK$10,017,000 in the same period of 2021[10]. - Administrative and other expenses totaled HK$6,504,000, down from HK$10,017,000 in the previous year[10]. - The company did not report any share of results from associates during the period, compared to a loss of HK$2,502,000 in the previous year[10]. Assets and Liabilities - As of September 30, 2022, total assets less current liabilities amounted to HK$265,365,000, compared to HK$263,557,000 as of March 31, 2022, reflecting a slight increase of 0.3%[16]. - Net current assets increased significantly to HK$237,376,000 from HK$157,665,000, representing a growth of 50.5%[16]. - The company reported a net cash used in operating activities of HK$41,300,000 for the six months ended September 30, 2022, compared to a net cash generated of HK$11,456,000 in the same period of 2021[27]. - Cash and cash equivalents at the end of the period were HK$112,152,000, up from HK$22,331,000 in the previous year, indicating a substantial increase of 403.5%[27]. - The company issued new shares, generating HK$26,365,000 in financing activities during the period[27]. - Total equity attributable to owners of the company decreased slightly to HK$261,199,000 from HK$262,283,000, a decline of 0.4%[19]. - The company’s inventories as of September 30, 2022, were HK$35,662,000, a significant increase from HK$10,000, indicating a rise of 256.6%[16]. - The company’s net assets stood at HK$262,017,000 as of September 30, 2022, compared to HK$263,384,000 as of March 31, 2022, showing a decrease of 0.5%[19]. - The company reported a net cash generated from investing activities of HK$95,170,000 for the period, a significant increase compared to HK$4,000 in the previous year[27]. - The company’s lease liabilities increased to HK$3,348,000 from HK$173,000, reflecting a substantial rise of 1,834.6%[16]. Segment Performance - For the six months ended September 30, 2022, the total turnover was HK$56,407,000, with external sales from healthcare products and services amounting to HK$56,359,000 and money lending business contributing HK$48,000[39]. - The segment profit for healthcare products and services was HK$633,000, while the money lending business reported a loss of HK$348,000, resulting in an overall segment profit of HK$285,000[39]. - The company incurred a loss before taxation of HK$1,341,000, after accounting for unallocated expenses of HK$1,635,000[39]. - The company is engaged in two operating segments: healthcare products and services, and money lending business, as per HKFRS 8[36]. - The healthcare business became the largest contributor to the Group's revenue, despite a 35.5% drop in revenue to HK$56.41 million due to the ongoing effects of the COVID-19 pandemic[119]. Changes in Accounting and Governance - The unaudited condensed consolidated financial statements have been prepared in accordance with Hong Kong Accounting Standards and relevant disclosure requirements[35]. - The company adopted new and revised Hong Kong Financial Reporting Standards effective from April 1, 2022, with no significant changes to accounting policies[35]. - The financial results should be read in conjunction with the 2022 annual financial statements for a comprehensive understanding of the company's performance[35]. - The Group's accounting policies for operating segments remain unchanged, ensuring consistency in financial reporting[42]. - The Company confirmed compliance with the Model Code for Securities Transactions by Directors during the six months ended September 30, 2022[149]. - The Company has adhered to the Corporate Governance Code during the reporting period, with minor deviations noted[142]. Shareholder Information - The Company did not declare or propose any dividends during the interim period[68]. - The weighted average number of ordinary shares increased to 1,408,610,000 as of 30 September 2022, up from 1,285,025,000 in 2021, indicating a 9.6% increase in shares[66]. - The Group completed a placement of 257,000,000 ordinary shares at HK$0.105 per share, raising approximately HK$13,515,000 after expenses[104]. - As of September 30, 2022, Pang Zhen held 285,004,080 ordinary shares, representing approximately 18.48% of the Company's shareholding[160]. - The Board did not recommend the payment of an interim dividend for the six months ended 30 September 2022[139]. Management and Operational Changes - The Group's key management personnel compensation decreased to HK$768,000 from HK$1,280,000, a reduction of 40%[108]. - Employee count decreased from 16 as of 30 September 2021 to 14 as of 30 September 2022[126]. - Mr. Li Li resigned as an independent non-executive director and committee member on April 25, 2022[177]. - Mr. Chan Man Kiu was appointed as an independent non-executive director and committee member on April 25, 2022[177]. - Mr. Yuan Limin was appointed as the chief executive officer and an executive director on July 29, 2022[177].

Financial Performance - For the fiscal year ending March 31, 2022, the total revenue was HKD 92,873 thousand, a decrease of 9.4% from HKD 102,041 thousand in the previous year[11]. - The company reported a net loss of HKD 31,260 thousand for the year, compared to a net loss of HKD 2,346 thousand in the previous year, indicating a significant decline in performance[4]. - The gross profit for the year was HKD 13,754 thousand, down from HKD 28,322 thousand in the previous year, reflecting a decrease of 51.4%[4]. - Revenue for the health products and services segment reached HKD 98,953,000, representing an increase from HKD 92,118,000 in the previous year, a growth of approximately 7.9%[19]. - The segment profit for health products and services was HKD 7,741,000, up from HKD 3,709,000, indicating a significant improvement in profitability[20]. - Total revenue for the company was HKD 102,041,000, compared to HKD 92,873,000 in the prior year, reflecting an overall growth of about 9.5%[20]. - The company reported a pre-tax profit of HKD 641,000 for the year, a turnaround from a pre-tax loss of HKD 30,629,000 in the previous year[20]. - The basic loss per share was HKD 0.0242, compared to HKD 0.0038 in the previous year, indicating a deterioration in earnings per share[31]. - The company reported a loss of approximately HKD 31,260,000 for the year, an increase of about HKD 28,910,000 compared to a loss of HKD 2,350,000 the previous year[49]. Assets and Liabilities - The company's total assets decreased to HKD 197,048 thousand from HKD 258,775 thousand, a decline of 23.8% year-over-year[6]. - The company's cash and cash equivalents increased to HKD 37,402 thousand from HKD 8,574 thousand, showing a significant improvement in liquidity[6]. - The company’s equity attributable to owners decreased to HKD 265,749 thousand from HKD 290,582 thousand, a reduction of 8.5%[6]. - Non-current assets in China increased to HKD 105,473,000 from HKD 54,341,000, showing a substantial growth of approximately 94.3%[23]. - The company’s total receivables increased to HKD 159,636,000 from HKD 173,378,000, reflecting a decrease in receivables[33]. - The provision for trade receivables at the end of the reporting period was HKD 139,000, up from HKD 133,000, indicating a slight increase in credit risk[35]. - The aging analysis of trade receivables showed that HKD 20,902,000 was overdue by more than 181 days as of March 31, 2022, compared to HKD 2,708,000 the previous year[38]. - The group's net current assets as of March 31, 2022, were approximately HKD 163,830,000, including cash and cash equivalents of about HKD 37,400,000, compared to HKD 228,450,000 and HKD 8,570,000 respectively as of March 31, 2021[63]. - The group had no debt as of March 31, 2022, resulting in a capital-to-debt ratio of zero, consistent with the previous year[63]. Operational Highlights - The company is primarily engaged in health products and services, as well as lending activities, with all revenue recognized in China[13]. - The health products and services business is expected to have broad prospects, driven by improving living standards and health awareness in China and globally[59]. - The group plans to use the proceeds from the sale of a 15% stake in Beijing Lianhe Zhongcheng Medical Technology Co., Ltd., valued at RMB 30,000,000, to enrich its general working capital and existing business[66]. - The company plans to expand and diversify its offerings in genetic testing and health data analysis products, as well as stem cell and innovative medical technology products[53]. - The group aims to continue identifying suitable new business opportunities and investment projects to maximize returns for shareholders[60]. - The group has reduced its workforce to 15 full-time employees as of March 31, 2022, down from 19 in the previous year, due to a focus on distributor sales marketing strategies[73]. Audit and Compliance - The company has not completed the audit procedures for the fiscal year, which may affect the publication of the audited financial results[2]. - The audit process for the fiscal year ending March 31, 2022, was adversely affected due to COVID-19 restrictions in mainland China, particularly in Beijing, where the company's headquarters are located[84]. - The unaudited full-year results for the fiscal year ending March 31, 2022, have not yet been agreed upon with the company's auditor, Zhonghui Anda CPA Limited[84]. - The company plans to announce the audited results for the fiscal year ending March 31, 2022, once the audit process is completed[85]. - The company will disclose any significant differences between the audited results and the unaudited results once they are available[85]. - The company will hold an annual general meeting, with the proposed date to be announced later[85]. - Arrangements for shareholder attendance and voting at the annual general meeting will be communicated separately[85]. Dividends and Contingent Liabilities - The company did not recommend any dividends for the fiscal year ending March 31, 2022, consistent with the previous year[29]. - The group has not proposed a final dividend for the year ending March 31, 2022, consistent with the previous year[61]. - The group has no significant contingent liabilities as of March 31, 2022[71]. - The group has not pledged any assets as collateral as of March 31, 2022[70].

Financial Performance - Total turnover for the six months ended September 30, 2021, was HK$87,492,000, a decrease of 4.9% compared to HK$91,746,000 in the same period of 2020[9]. - Gross profit for the period was HK$8,813,000, down 37.5% from HK$14,059,000 in the previous year[9]. - Operating loss for the period was HK$3,732,000, compared to an operating profit of HK$3,185,000 in the same period of 2020[9]. - The net loss for the period was HK$4,590,000, a significant decline from a profit of HK$1,746,000 in the prior year[9]. - Total comprehensive income for the period was a loss of HK$1,147,000, compared to a comprehensive income of HK$13,790,000 in the same period of 2020[11]. - Basic and diluted loss per share was HK$0.36, compared to a restated profit of HK$0.03 per share in the previous year[11]. - The Group's loss for the six months ended 30 September 2021 was approximately HK$4.59 million, a decrease of approximately HK$6.34 million compared to a profit of HK$1.75 million in the previous interim period[99]. - The decrease in loss was primarily due to reduced revenue from both healthcare services and money lending businesses, along with increased administrative expenses primarily from higher staff costs[99]. Assets and Liabilities - Non-current assets decreased from HK$1,129,000 to HK$777,000, a decline of approximately 31.2%[13]. - Current assets increased from HK$258,775,000 to HK$269,640,000, an increase of about 4.5%[13]. - Net current assets rose from HK$228,453,000 to HK$230,948,000, reflecting a growth of 1.1%[13]. - Total equity attributable to owners of the Company decreased slightly from HK$290,582,000 to HK$289,524,000, a decrease of 0.4%[13]. - The company’s total liabilities increased from HK$30,322,000 to HK$38,692,000, an increase of approximately 27.8%[13]. - As of September 30, 2021, the Group had bank balances and cash of approximately HK$21.17 million, an increase from approximately HK$8.57 million as of March 31, 2021[116]. - The Group had no borrowings as of September 30, 2021, resulting in a gearing ratio of 0[116]. Revenue Segments - The healthcare products and services business is one of the three operating segments, alongside money lending and securities trading and investments[33]. - The healthcare products and services business remains the largest contributor to the Group's revenue, although it experienced a slight decline due to the ongoing effects of the COVID-19 pandemic[100]. - For the healthcare segment, turnover was HK$86.74 million, down from HK$90.20 million in the same period last year, with segment profit decreasing to HK$3.81 million from HK$10.23 million[107]. - The money lending business recorded a turnover of interest income of HK$0.76 million for the six months ended 30 September 2021, down from HK$1.54 million for the same period in 2020[109]. Operational Efficiency and Strategy - The company is focusing on improving operational efficiency and exploring new market opportunities to enhance future performance[10]. - The Group intends to diversify its genetic testing and health data analysis products and expand into international markets to provide more comprehensive services[107]. - The Group's financial performance indicates a robust growth trajectory, supported by increased receivables and effective credit management strategies[67]. - The overall financial performance reflects challenges faced in the healthcare sector, necessitating strategic adjustments to enhance revenue streams and operational efficiency[100]. Corporate Governance and Compliance - The Group's financial statements are prepared in accordance with Hong Kong Accounting Standard 34, ensuring compliance with relevant disclosure requirements[25]. - The Group has not applied any new or revised HKFRSs that are not yet effective for the current interim period, maintaining consistency in accounting policies[25]. - The Board has approved the unaudited condensed consolidated financial statements for the six months ended 30 September 2021, prepared in accordance with generally accepted accounting standards in Hong Kong[114]. - The Group's independent audit committee reviewed the unaudited condensed consolidated financial statements for the six months ended September 30, 2021[121]. - The company confirmed compliance with the Model Code for Securities Transactions by Directors during the six months ended September 30, 2021[125]. - The company has taken sufficient measures to ensure corporate governance practices comply with the corporate governance code[126]. Shareholder Information - The substantial shareholders included Pang Zhen with 22.18% (285,004,080 shares), Zhou Chunyan with 19% (244,212,611 shares), and Pioneer Environmental International Industries Company Limited with 12.46% (160,120,000 shares)[132]. - The company adopted a new Share Option Scheme on September 18, 2012, valid for ten years, allowing the issuance of up to 107,085,706 shares upon exercise of options[136]. - No share options were exercised during the six months ended September 30, 2021, leaving 86,040,000 options outstanding[139]. - The refreshment of the scheme mandate limit was approved on September 7, 2018, allowing for the issuance of 535,428,530 shares, representing 10% of the issued shares at that time[138]. Changes in Management - Ms. Zheng Xin resigned as an independent non-executive director on 31 August 2021[142]. - Mr. Li Li was appointed as an independent non-executive director on 31 August 2021[142]. - Mr. Man Wai Lun was appointed as an independent non-executive director of Momentum Financial Holdings Limited on 27 August 2021[142]. - Mr. Man Wai Lun was appointed as an executive director of Century Group International Holdings Limited on 1 October 2021[142].

nd 100 莲机医疗 Life Healthcare ANI 年 Life Healthcare Group Limited 蓮和醫療健康集團有限公司 (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立之有限公司) Stock Code 股份代碼 :00928 HIMMANNA WANNA PECIEL HITT 蓮和醫療健康集團有限公司 2021年年度報告 Contents 目錄 Corporate Information 公司資料 2 Management Discussion and Analysis 管理層討論及分析 4 Biographical Details of Directors 董事履歷詳情 18 Directors' Report 董事會報告 21 Corporate Governance Report 企業管治報告 40 Environmental, Social and Governance Report 環境、社會及管治報告 56 Independent Auditor's Report 獨立 ...

t INTERIM REPORT 中 期 報 告 . ● i • ● . ● ● ● ● ● · ● ● ● ● Healthcare Life Healthcare Group Limited 蓮和醫療健康集團有限公司 (Incorporated in the Cayman Islands with Iimited liability) (於開曼群島註冊成立之有限公司) Stock Code 股份代碼 :00928 | --- | --- | --- | |--------------------------------------------------------|------------------------------|--------------------------| | | | 蓮和醫療健康集團有限公司 | | | | 2020年中期報告 | | | | Contents | | | | 目錄 | | Corporate Information | 公司資料 | 2 | | Condensed Consolidated Statement of Profit or Loss and | 簡 ...

. · t and the subject of the states of the subject of th 2020 ANNUAL REPORT 度 Life Healthcare Group Limited 蓮和醫療健康集團有限公司 (Incorporated in the Cayman Islands with Iimited liability) (於開曼群島註冊成立之有限公司) Stock Code 股份代碼 :00928 蓮和醫療健康集團有限公司 2020年年度報告 Contents 目錄 Corporate Information 公司資料 2 Management Discussion and Analysis 管理層討論及分析 4 Biographical Details of Directors 董事履歷詳情 16 Directors' Report 董事會報告 19 Corporate Governance Report 企業管治報告 42 Environmental, Social and Governance Report 環境、社會及管治報告 59 Independent Au ...

Financial Performance - For the six months ended September 30, 2019, the company reported a turnover of HK$6,810,000, a decrease of 84.6% compared to HK$44,024,000 in the same period of 2018[12]. - The gross profit for the same period was HK$5,320,000, down from HK$28,483,000, reflecting a significant decline in profitability[12]. - The loss before taxation for the period was HK$12,406,000, compared to a loss of HK$69,012,000 in the previous year, indicating an improvement in financial performance[12]. - The total comprehensive expense for the period was HK$26,204,000, a decrease from HK$86,321,000 in the prior year, showing a reduction in overall losses[14]. - The loss attributable to equity holders of the company from continuing operations was HK$12,454,000, compared to HK$67,863,000 in the same period last year, indicating a narrowing of losses[12]. - The company reported a basic and diluted loss per share of HK$0.23 for the period, consistent with the previous year's loss per share[12]. - The company reported a loss for the period of HK$12,454,000, compared to a loss of HK$65,359,000 in the previous period[26]. - The segment loss for continuing operations was HK$29,915,000, with a significant impairment loss on interest in an associate amounting to HK$17,080,000[107]. - The Group's loss for the interim period was approximately HK$12.45 million, a decrease of approximately 81.40% from HK$66.95 million in the previous interim period[185]. Cost Management - The administrative and other expenses amounted to HK$15,092,000, a decrease from HK$39,251,000 in the prior year, reflecting cost control measures[12]. - The company experienced a significant reduction in selling and distribution costs, which totaled HK$31,627,000, down from HK$15,541,000 in the previous year[12]. - The overall financial position shows a positive trend with increased cash reserves and improved cash flow from operations[45]. Assets and Liabilities - As of September 30, 2019, total assets less current liabilities amounted to HK$264,306,000, a decrease of 8.34% from HK$288,341,000 as of March 31, 2019[15]. - Current assets decreased to HK$222,113,000 from HK$240,519,000, reflecting a decline of 7.66%[15]. - The company's net current assets were HK$207,426,000, down from HK$228,274,000, indicating a decrease of 9.12%[15]. - Non-current assets totaled HK$56,880,000, a decrease of 5.67% from HK$60,067,000[15]. - Total equity attributable to owners of the Company was HK$262,137,000, down from HK$288,341,000, reflecting a decrease of 9.09%[19]. - The reserves decreased to HK$208,594,000 from HK$234,798,000, a decline of 11.14%[19]. - The interest in associates decreased to HK$30,898,000 from HK$35,783,000, a reduction of 13.76%[15]. - The company's inventories decreased to HK$1,552,000 from HK$1,856,000, indicating a decline of 16.38%[15]. Cash Flow - Net cash generated from operating activities was HK$185,229, compared to a cash outflow of HK$34,267 in the same period last year[45]. - Net cash generated from investing activities was HK$161, a significant improvement from a cash outflow of HK$1,091 in the previous year[45]. - Cash and cash equivalents at 30 September amounted to HK$194,123, an increase from HK$36,757 at the same time last year[45]. - The effect of foreign exchange rate changes contributed HK$21,065 to cash and cash equivalents, compared to a negative impact of HK$10,755 in the previous year[45]. Business Segments - The company is primarily engaged in healthcare services, money lending, and securities trading and investment[49]. - The healthcare services segment generated external sales of HK$2,570,000, while the money lending business reported external sales of HK$4,240,000[100]. - The Group's operating segments include healthcare services, money lending, and securities trading and investments[100]. - The healthcare services segment recorded a turnover of HK$2.57 million, down from HK$38.12 million in the previous year, with a segment loss of HK$7.24 million[190]. - The money lending business generated a turnover of interest income of HK$4.24 million, down from HK$5.90 million in the previous year, maintaining a gross profit margin of 100%[192]. Future Outlook - The company is focusing on improving operational efficiency and reducing costs to enhance future profitability[12]. - The management expressed optimism about future performance improvements as the company implements new strategies and operational adjustments[12]. - The Group plans to enhance its sales strategy by focusing on distributor sales to penetrate major cities in the PRC, which may temporarily affect revenue during the transition[190]. - The Group aims to expand and diversify its genetic testing and health data analysis products to provide more comprehensive services to customers[190]. - The management will continue to seek new business opportunities and investment projects suitable for the Company[195]. Compliance and Accounting - The financial statements are prepared in accordance with Hong Kong Accounting Standard 34, ensuring compliance with applicable disclosure requirements[49]. - The company adopted new accounting standards effective from 1 April 2019, including HKFRS 16 on leases, which may impact future financial reporting[53]. - The Group adopted HKFRS 16 from April 1, 2019, recognizing lease liabilities previously classified as operating leases[60]. - The Group did not restate comparative information for the 2018 reporting period as permitted under the simplified transition approach[60]. - The Board has approved the unaudited condensed consolidated financial statements for the six months ended September 30, 2019, prepared in accordance with Hong Kong generally accepted accounting standards[200].